Syngene International Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Virtually debt-free
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SYNGENE · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 54.79% | 54.79% | 54.72% | 54.72% | 52.74% | 52.74% |
| FII | 21.20% | 20.92% | 20.64% | 20.72% | 20.65% | 19.47% |
| DII | 14.63% | 15.80% | 16.78% | 17.49% | 19.52% | 21.50% |
| Public | 9.07% | 8.18% | 7.44% | 6.74% | 6.79% | 5.99% |
| Others | 0.32% | 0.31% | 0.43% | 0.34% | 0.29% | 0.29% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 1.25 Per Share
Record: 25 Jun 2026
Dividend - Rs 1.25 Per Share
Dividend - Rs 1.25 Per Share
Dividend - Rs 0.50 Per Share/Special Dividend - Rs 0.75 Per Share
Latest News
All newsSynergy Green to host analyst and investor meet
*Synergy Green to host analyst and investor meet.* The company has announced a schedule for its upcoming analyst and institutional investor call. **No financial updates or major announcements** were disclosed in the filing. The event aims to provide insights on business performance and future outlook. 📊 *STOCKS:* $SYNGENE | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #InvestorMeet
Syngene shares unchanged after analyst meeting update
*Syngene shares unchanged after analyst meeting update.* The company disclosed a recent interaction with analysts and institutional investors, providing general business updates. No financial figures or strategic changes were announced. The filing was routine and did not include material news. 📊 *STOCKS:* $SYNGENE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnalystMeeting
Syngene to host analyst and investor meet
*Syngene to host analyst and investor meet* to discuss business updates and strategy. The event is part of routine investor engagement. No financial announcements or major updates were disclosed. Schedule details are available in the NSE filing. 📊 *STOCKS:* $SYNGENE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnalystMeet
Synergy Green hosts analyst call; no major updates disclosed
*Synergy Green hosts analyst call; no major updates disclosed.* The company shared operational insights during its investor meet, with no significant financial or strategic announcements. Recording of the call is available online for interested stakeholders. **No material data on earnings, guidance, or capex was released.** 📊 *STOCKS:* $SYNGENE | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #ConferenceCall
Synergy Green Industries issues general updates
*Synergy Green Industries issues general updates.* The company filed routine corporate updates with the NSE. No specific financial or operational details were disclosed. Such filings typically involve administrative or procedural information. 📊 *STOCKS:* $SYNGENE | 🏢 *SECTOR:* Corporate | #LOWIMPACT #corporate
Syngene International holds AGM, submits voting results
*Syngene International holds AGM, submits voting results*. Syngene International Limited has filed the scrutinizer's report of its Annual General Meeting held on **July 29, 2026**, with the stock exchange. The company disclosed the voting outcomes from the meeting. This is a routine corporate disclosure with no immediate financial implications. 📊 *STOCKS:* $SYNGENE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.0K Cr 13.0% | ₹917.1 Cr 0.7% | ₹910.6 Cr 4.1% | ₹874.5 Cr 14.1% | ₹1.0K Cr 7.9% | ₹943.7 Cr 5.9% | ₹891 Cr 12.8% | ₹790 Cr |
| Op. Profit | ₹303.4 Cr 45.0% | ₹209.2 Cr 4.9% | ₹199.5 Cr 3.3% | ₹206.4 Cr 39.9% | ₹343.6 Cr 21.2% | ₹283.6 Cr 15.8% | ₹244.8 Cr 44.0% | ₹170 Cr |
| OPM | 29.3% 28.3% | 22.8% 4.1% | 21.9% 7.2% | 23.6% 30.1% | 33.8% 12.3% | 30.1% 9.4% | 27.5% 24.9% | 22.0% |
| Net Profit | ₹147.9 Cr 886.0% | ₹15 Cr 77.6% | ₹67.1 Cr 22.6% | ₹86.7 Cr 52.7% | ₹183.3 Cr 39.8% | ₹131.1 Cr 23.6% | ₹106.1 Cr 39.6% | ₹76 Cr |
| EPS (₹) | 3.67 891.9% | 0.37 77.8% | 1.67 22.3% | 2.15 52.7% | 4.55 39.6% | 3.26 23.5% | 2.64 40.4% | 1.88 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.7K Cr 2.7% | ₹3.6K Cr 4.4% | ₹3.5K Cr 9.3% | ₹3.2K Cr 22.6% | ₹2.6K Cr 19.2% | ₹2.2K Cr 8.5% | ₹2.0K Cr 10.2% | ₹1.8K Cr 28.3% | ₹1.4K Cr |
| Expenses | ₹2.8K Cr 8.4% | ₹2.6K Cr 5.1% | ₹2.5K Cr 9.8% | ₹2.3K Cr 21.0% | ₹1.9K Cr 23.5% | ₹1.5K Cr 8.1% | ₹1.4K Cr 8.1% | ₹1.3K Cr 35.8% | ₹949 Cr |
| Op. Profit | ₹921 Cr 11.9% | ₹1.0K Cr 2.8% | ₹1.0K Cr 8.0% | ₹942 Cr 26.8% | ₹743 Cr 9.6% | ₹678 Cr 9.7% | ₹618 Cr 15.1% | ₹537 Cr 13.3% | ₹474 Cr |
| OPM | 25.0% 13.8% | 29.0% 0.0% | 29.0% 3.3% | 30.0% 3.4% | 29.0% 6.5% | 31.0% 0.0% | 31.0% 6.9% | 29.0% 12.1% | 33.0% |
| Other Income | ₹-9 Cr 108.9% | ₹101 Cr 31.2% | ₹77 Cr 22.2% | ₹63 Cr 16.0% | ₹75 Cr 20.2% | ₹94 Cr 38.6% | ₹153 Cr 104.0% | ₹75 Cr 41.5% | ₹53 Cr |
| Interest | ₹49 Cr 7.5% | ₹53 Cr 12.8% | ₹47 Cr 4.4% | ₹45 Cr 87.5% | ₹24 Cr 14.3% | ₹28 Cr 20.0% | ₹35 Cr 9.4% | ₹32 Cr 39.1% | ₹23 Cr |
| Depreciation | ₹453 Cr 4.6% | ₹433 Cr 1.6% | ₹426 Cr 16.4% | ₹366 Cr 18.1% | ₹310 Cr 13.1% | ₹274 Cr 25.1% | ₹219 Cr 33.5% | ₹164 Cr 25.2% | ₹131 Cr |
| PBT | ₹411 Cr 37.7% | ₹660 Cr 6.3% | ₹621 Cr 4.5% | ₹594 Cr 22.7% | ₹484 Cr 3.2% | ₹469 Cr 9.3% | ₹517 Cr 24.6% | ₹415 Cr 11.6% | ₹372 Cr |
| Tax % | 23.0% 8.0% | 25.0% 38.9% | 18.0% 18.2% | 22.0% 22.2% | 18.0% 28.6% | 14.0% 30.0% | 20.0% 0.0% | 20.0% 11.1% | 18.0% |
| Net Profit | ₹317 Cr 36.1% | ₹496 Cr 2.7% | ₹510 Cr 9.9% | ₹464 Cr 17.2% | ₹396 Cr 2.2% | ₹405 Cr 1.7% | ₹412 Cr 24.1% | ₹332 Cr 8.9% | ₹305 Cr |
| EPS (₹) | 7.86 36.3% | 12.33 2.8% | 12.69 9.7% | 11.57 17.1% | 9.88 2.4% | 10.12 1.7% | 10.3 24.2% | 8.29 8.5% | 7.64 |
| Div Payout | 16.0% 60.0% | 10.0% 0.0% | 10.0% 9.1% | 11.0% 10.0% | 10.0% | 0.0% | 0.0% 100.0% | 3.0% 57.1% | 7.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|
Liabilities | |||||||||
| Equity Capital | ₹403 Cr 0.2% | ₹402 Cr 0.0% | ₹402 Cr 0.2% | ₹401 Cr 0.0% | ₹401 Cr 0.3% | ₹400 Cr 0.0% | ₹400 Cr 100.0% | ₹200 Cr 0.0% | ₹200 Cr |
| Reserves | ₹4.4K Cr 2.6% | ₹4.3K Cr 12.1% | ₹3.9K Cr 19.9% | ₹3.2K Cr 11.0% | ₹2.9K Cr 19.7% | ₹2.4K Cr 36.3% | ₹1.8K Cr 0.5% | ₹1.8K Cr 16.3% | ₹1.5K Cr |
| Borrowings | ₹458 Cr 20.8% | ₹578 Cr 4.1% | ₹555 Cr 31.9% | ₹815 Cr 20.3% | ₹1.0K Cr 14.4% | ₹893 Cr 15.5% | ₹773 Cr 4.9% | ₹813 Cr 3.3% | ₹787 Cr |
| Other Liabilities | ₹1.8K Cr 17.8% | ₹1.5K Cr 11.4% | ₹1.3K Cr 4.2% | ₹1.4K Cr 12.3% | ₹1.2K Cr 6.5% | ₹1.2K Cr 3.7% | ₹1.2K Cr 31.7% | ₹922 Cr 35.4% | ₹681 Cr |
| Total Liabilities | ₹7.1K Cr 3.8% | ₹6.8K Cr 10.5% | ₹6.2K Cr 5.5% | ₹5.8K Cr 4.8% | ₹5.6K Cr 13.9% | ₹4.9K Cr 17.3% | ₹4.2K Cr 12.4% | ₹3.7K Cr 16.1% | ₹3.2K Cr |
Assets | |||||||||
| Fixed Assets | ₹3.0K Cr 7.1% | ₹2.8K Cr 1.7% | ₹2.9K Cr 6.9% | ₹2.7K Cr 11.5% | ₹2.4K Cr 8.7% | ₹2.2K Cr 9.0% | ₹2.0K Cr 46.7% | ₹1.4K Cr 33.7% | ₹1.0K Cr |
| CWIP | ₹1.0K Cr 17.4% | ₹1.3K Cr 51.1% | ₹838 Cr 373.4% | ₹177 Cr 48.8% | ₹346 Cr 46.0% | ₹237 Cr 1.3% | ₹234 Cr 14.6% | ₹274 Cr 76.8% | ₹155 Cr |
| Investments | ₹741 Cr 14.5% | ₹647 Cr 18.1% | ₹548 Cr 40.3% | ₹918 Cr 11.2% | ₹1.0K Cr 47.3% | ₹702 Cr 9.5% | ₹776 Cr 8.4% | ₹716 Cr 353.2% | ₹158 Cr |
| Other Assets | ₹2.3K Cr 9.0% | ₹2.1K Cr 8.6% | ₹1.9K Cr 7.4% | ₹2.1K Cr 15.6% | ₹1.8K Cr 2.7% | ₹1.7K Cr 53.8% | ₹1.1K Cr 15.3% | ₹1.3K Cr 27.6% | ₹1.8K Cr |
| Total Assets | ₹7.1K Cr 3.8% | ₹6.8K Cr 10.5% | ₹6.2K Cr 5.5% | ₹5.8K Cr 4.8% | ₹5.6K Cr 13.9% | ₹4.9K Cr 17.3% | ₹4.2K Cr 12.4% | ₹3.7K Cr 16.1% | ₹3.2K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹915 Cr 21.7% | ₹1.2K Cr 12.1% | ₹1.0K Cr 26.5% | ₹824 Cr 41.8% | ₹581 Cr 17.1% | ₹701 Cr 3.5% | ₹677 Cr 7.5% | ₹630 Cr 41.3% | ₹446 Cr |
| Investing CF | ₹-839 Cr 12.8% | ₹-744 Cr 50.6% | ₹-494 Cr 24.3% | ₹-653 Cr 6.9% | ₹-611 Cr 2.9% | ₹-629 Cr 48.3% | ₹-424 Cr 34.4% | ₹-646 Cr 85.1% | ₹-349 Cr |
| Financing CF | ₹-215 Cr 51.4% | ₹-142 Cr 74.2% | ₹-551 Cr 61.1% | ₹-342 Cr 1003.2% | ₹-31 Cr 153.4% | ₹58 Cr 125.7% | ₹-226 Cr 213.9% | ₹-72 Cr 8.9% | ₹-79 Cr |
| Net Cash Flow | ₹-138 Cr 149.1% | ₹281 Cr 7125.0% | ₹-4 Cr 97.7% | ₹-172 Cr 177.4% | ₹-62 Cr 147.7% | ₹130 Cr 364.3% | ₹28 Cr 131.8% | ₹-88 Cr 588.9% | ₹18 Cr |
| Free Cash Flow | ₹547 Cr 37.4% | ₹398 Cr 28.0% | ₹553 Cr 81.3% | ₹305 Cr 190.5% | ₹105 Cr 58.8% | ₹255 Cr 650.0% | ₹34 Cr 27.7% | ₹47 Cr 42.7% | ₹82 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 50d 5.7% | 53d 15.2% | 46d 24.6% | 61d 14.1% | 71d 10.1% | 79d 9.7% | 72d 5.9% | 68d 0.0% | 68d |
| Inventory Days | 56d 6.7% | 60d 36.2% | 94d 33.3% | 141d 62.1% | 87d 112.2% | 41d 127.8% | 18d 40.0% | 30d 63.4% | 82d |
| Days Payable | 138d 1.5% | 136d 36.0% | 100d 8.3% | 109d 3.5% | 113d 32.3% | 167d 7.1% | 156d 1.3% | 154d 21.0% | 195d |
| Cash Conv. Cycle | -32d 39.1% | -23d 157.5% | 40d 56.5% | 92d 104.4% | 45d 195.7% | -47d 28.8% | -66d 17.9% | -56d 27.3% | -44d |
| Working Capital Days | -68d 33.3% | -51d 88.9% | -27d 92.9% | -14d 67.4% | -43d 34.8% | -66d 61.6% | -172d 67.0% | -103d 114.6% | -48d |
| ROCE | 10.0% 23.1% | 13.0% 13.3% | 15.0% 0.0% | 15.0% 15.4% | 13.0% 7.1% | 14.0% 17.6% | 17.0% 0.0% | 17.0% | — |
Source: Screener.in · Lower days = better efficiency